Skip to main content

Table 3 Comparisons of quality of life and symptoms between the different medical care of patients: Results from questionnaires

From: Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

Score Active surveillance Radical prostatectomy Radiotherapy or Brachytherapy or HIFU or ADT Combined care p-value
QLQ-C30
 Summary score QLQ-C30 97.44 [94.83; 100] 95.51 [87.65; 98.72] 92.31 [87.44; 97.78] 93.25 [84.44; 98.72] 0.0192
 Global health status/QOL: Poorer global health (<=83.3), n (%) 6 (15.4) 58 (31.2) 18 (34) 35 (38.9) 0.0694
 Physical Functioning: score < 100, n (%) 10 (25.6) 60 (32.3) 27 (50.9) 36 (40.5) 0.0319
 Role Functioning: score < 100, n (%) 5 (12.8) 37 (19.9) 11 (20.8) 17 (19.1) 0.76
 Emotional Functioning: score < 100, n (%) 18 (46.2) 102 (54.8) 28 (52.8) 53 (58.9) 0.60
 Cognitive Functioning: score < 100, n (%) 11 (28.2) 79 (42.7) 27 (50.9) 51 (56.7) 0.0153
 Social Functioning: score < 100, n (%) 5 (12.8) 46 (24.7) 12 (22.6) 28 (31.1) 0.1671
 Fatigue: score > 0, n (%) 12 (30.8) 88 (47.3) 28 (52.8) 38 (42.2) 0.1589
 Nausea/Vomiting: score > 0, n (%) 1 (2.6) 5 (2.7) 2 (3.8) 8 (8.9) 0.1320*
 Pain: score > 0, n (%) 9 (23.1) 42 (22.6) 12 (22.6) 23 (25.6) 0.96
 Dyspnea: score > 0, n (%) 6 (15.4) 37 (20) 17 (32.1) 22 (24.7) 0.1834
 Insomnia: score > 0, n (%) 10 (25.6) 60 (32.3) 20 (37.7) 36 (40) 0.36
 Appetite loss: score > 0, n (%) 1 (2.6) 10 (5.4) 2 (3.9) 6 (6.7) 0.88*
 Constipation: score > 0, n (%) 1 (2.6) 38 (20.5) 9 (17) 17 (18.9) 0.0640
 Diarrhea: score > 0, n (%) 7 (18) 23 (12.5) 11 (21.2) 12 (13.3) 0.40
 Financial Problems: score > 0, n (%) 2 (5.3) 11 (6) 2 (3.9) 7 (8.1) 0.80*
IPSS
 Mild 23 (63.9) 137 (76.5) 28 (60.9) 63 (75)  
 Moderate 9 (25) 37 (20.7) 13 (28.3) 15 (17.9) 0.0730
 Severe 4 (11.1) 5 (2.8) 5 (10.9) 6 (7.1)  
ICIQ-MLUTS
 Voiding score (VS) 4 [1; 7] 2 [0; 4] 3.5 [2; 6] 3 [1; 5] 0.0011
 Incontinence score (IS) 3 [0; 4] 4 [2; 6] 2 [1;4] 2 [1.5; 6] < 0.0001
 Frequency of diurnal urination
  - 1–6 times per day 22 (56.4) 106 (59.2) 30 (55.6) 51 (58.6)  
  - 7–8 times per day 13 (33.3) 50 (27.9) 17 (31.5) 26 (29.9) 0.99
  - ≥9 times per day 4 (10.3) 23 (12.9) 7 (13) 10 (11.5)  
 Frequency of nocturnal urination
  - Never 7 (18) 44 (24.3) 8 (15.1) 15 (16.9)  
  - 1 time per night 19 (48.7) 89 (49.2) 23 (43.4) 55 (61.8) 0.0925
  - ≥ 2 times per night 13 (33.3) 48 (26.5) 22 (41.5) 19 (21.4)  
IIEF-6
 No dysfunction 9 (23.1) 11 (5.9) 5 (9.3) 9 (10)  
 Mild, Mild to moderate, or Moderate dysfunction 17 (43.6) 25 (13.4) 14 (25.9) 16 (17.8) < 0.0001
 Severe Erectile dysfunction 13 (33.3) 151 (80.8) 35 (64.8) 65 (72.2)  
HADS
 HADS anxiety
  - Absence of anxiety 31 (81.6) 124 (71.3) 42 (82.4) 64 (74.4)  
  - Suspected anxiety 6 (15.8) 32 (18.4) 7 (13.7) 13 (15.1) 0.49
  - Probable anxiety 1 (2.6) 18 (10.3) 2 (3.9) 9 (10.5)  
 HADS depression
  - Absence of anxiety 33 (86.8) 145 (81.5) 44 (89.8) 75 (88.2)  
  - Suspected anxiety 5 (13.2) 19 (10.7) 3 (6.1) 9 (10.6) 0.1588
  - Probable anxiety 0 14 (7.9) 2 (4.1) 1 (1.2)  
 HADS Total score
  - Absence of anxio-depressive troubles 33 (86.8) 130 (76.9) 40 (85.1) 69 (83.1) 0.34
  - Presence of anxio-depressive troubles 5 (13.2) 39 (23.1) 7 (14.9) 14 (16.9)  
  1. Data presented as number (%) or median [IQR] as appropriate. * Fisher test; Khi2 test otherwise